一种联合性的胰高血糖素瘤和血管活性肠肽瘤综合征。首例病理及临床报告。

A combined glucagonoma and VIPoma syndrome. First pathologic and clinical report.

作者信息

Cavallo-Perin P, De Paoli M, Guiso G, Sapino A, Papotti M, Coda R, Pagano G

机构信息

Institute of Internal Medicine, University of Turin, Italy.

出版信息

Cancer. 1988 Dec 15;62(12):2576-9. doi: 10.1002/1097-0142(19881215)62:12<2576::aid-cncr2820621221>3.0.co;2-5.

DOI:10.1002/1097-0142(19881215)62:12<2576::aid-cncr2820621221>3.0.co;2-5

PMID:2847862

Abstract

We report a case of pancreatic tumour metastatic to the liver in a patient with insulin-treated diabetes, anaemia, cheilitis, necrolytic migratory erythema, hypokalemia and chronic watery diarrhea, a picture suggesting combined glucagonoma and VIPoma syndromes. Immunocytochemistry of a biopsied hepatic metastatic nodule revealed both glucagon and vasoactive intestinal peptide (VIP) positive cells. Increased plasma glucagon and VIP levels were detected (values of 900 pmol/l and 277 pmol/l respectively). This is the first reported case showing not only immunocytochemical, but also clinical evidence of the combined secretion of these hormones.

摘要

我们报告一例患有胰岛素治疗的糖尿病、贫血、唇炎、坏死性游走性红斑、低钾血症和慢性水样腹泻的患者，其胰腺肿瘤转移至肝脏，这一情况提示合并有胰高血糖素瘤和血管活性肠肽瘤综合征。对肝脏转移结节活检的免疫细胞化学检查显示胰高血糖素和血管活性肠肽（VIP）阳性细胞均存在。检测到血浆胰高血糖素和VIP水平升高（分别为900 pmol/l和277 pmol/l）。这是首例不仅有免疫细胞化学证据，而且有这些激素联合分泌的临床证据的报告病例。